The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS
申请人:Bristol-Myers Squibb Company
公开号:EP1954696B1
公开(公告)日:2011-02-23
US7645778B2
申请人:——
公开号:US7645778B2
公开(公告)日:2010-01-12
US8273772B2
申请人:——
公开号:US8273772B2
公开(公告)日:2012-09-25
[EN] 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS<br/>[FR] COMPOSES HETEROARYLE TENANT LIEU D'INHIBITEURS DU RECEPTEUR P2Y1
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2006078621A2
公开(公告)日:2006-07-27
(EN) The present invention provides novel heteroaryl compounds of formula (Ia) which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity. (Ia) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 ringheteroatoms selected from N, NR11, S(O)p, and O, wherein said heteroaryl is substituted with 0-4 R1; ring B is phenyl substituted with 0-4 R7, pyridyl substituted with 0-3 R7, or thienyi substituted with 0-2 R7; X is NH or NMe; Y is O or S; R5 is a -(CRfRf)n-C3-10 carbocycle substituted with 1-4 R5a, or a -(CRfRf)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-4 R5a; the other substituents and variables are defined in the claims.(FR) Nouveaux composés hétéroaryle et leurs analogues qui sont des inhibiteurs sélectifs du récepteur humain P2Y1. Différentes compositions pharmaceutiques les contenant est méthodes de traitement de maladies réagissant à la modulation de l'activité du récepteur P2Y1.